Quinolone‑Associated Tendonitis

Overview

Quinolone‑associated tendonitis is an inflammation of a tendon that occurs as an adverse reaction to the class of antibiotics known as fluoroquinolones (e.g., ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin). While these drugs are highly effective against a broad range of bacterial infections, they carry a recognized risk of tendon injury, ranging from mild inflammation (tendonitis) to complete tendon rupture.

Who it affects: Adults of any age can develop the condition, but the risk is highest in people over 60 years old, in those taking systemic (oral or intravenous) fluoroquinolones, and in patients with additional risk factors such as steroid use, renal disease, or diabetes.

Prevalence: Post‑marketing surveillance and large database studies estimate that fluoroquinolone‑related tendon disorders occur in roughly 0.1–0.5 % of treated patients, with tendon rupture being about ten‑fold less common (FDA, 2016). In the United States, more than 30,000 tendon‑related adverse events were reported to the FDA between 2000–2017.

Symptoms

Symptoms typically develop during treatment or up to several weeks after the last dose. They may be unilateral or affect multiple sites.

• Localized pain – aching or sharp pain that worsens with movement.
• Tenderness to touch – the tendon feels sore when pressed.
• Swelling or thickening – visible puffiness or a palpable “rope‑like” enlargement.
• Stiffness – reduced range of motion, especially after periods of inactivity.
• Crepitus – a crackling sensation felt when the tendon moves.
• Weakness – difficulty bearing weight or performing normal activities (e.g., walking, gripping).
• Audible snapping or “pop” – may signal a partial or complete tendon tear, a medical emergency.

The most commonly involved tendons are:

• The Achilles tendon (≈ 70 % of cases)
• The rotator cuff tendons of the shoulder
• The patellar tendon (knee)
• The biceps brachii tendon

Causes and Risk Factors

Mechanism of injury

Fluoroquinolones interfere with collagen synthesis and increase matrix metalloproteinase activity, leading to weakened tendon fibers. Oxidative stress and direct toxicity to tenocytes (tendon cells) are also implicated (NIH, 2015).

Key risk factors

• Age ≥ 60 years – age‑related tendon degeneration.
• Concurrent corticosteroid therapy – synergistic weakening of tendon tissue.
• Renal insufficiency or dialysis – reduced drug clearance, higher serum levels.
• Diabetes mellitus – microvascular changes affecting tendon health.
• History of tendon disorders or previous fluoroquinolone exposure.
• High‑dose or prolonged fluoroquinolone courses (≥ 7 days for most oral agents).
• Physical activity during treatment – especially high‑impact sports or heavy lifting.

Diagnosis

Diagnosis is primarily clinical, supported by imaging when uncertainty exists.

Step‑by‑step evaluation

1. Medical history – document fluoroquinolone use (drug, dose, duration), onset of symptoms, and risk factors.
2. Physical examination – palpation of the tendon, assessment of pain with passive/active motion, and provocative tests (e.g., Thompson test for Achilles).
3. Imaging:
   • Ultrasound – readily available, shows tendon thickening, hypoechoic areas, or partial tears.
   • MRI – gold standard for detailed evaluation; detects edema, intratendinous fluid, and full‑thickness ruptures.
4. Laboratory tests – not diagnostic but may rule out infection or systemic inflammation (CBC, ESR, CRP).

Treatment Options

Treatment aims to halt progression, relieve pain, and restore function.

Immediate measures

• Discontinue the fluoroquinolone – switch to an alternative antibiotic based on culture/sensitivity.
• Immobilization – use a brace, splint, or walking boot to reduce stress on the affected tendon.
• Ice therapy – 15‑20 min every 2‑3 hours during the first 48 h to reduce inflammation.

Pharmacologic therapy

• NSAIDs (e.g., ibuprofen 400–600 mg q6h) for pain and inflammation, unless contraindicated.
• Acetaminophen as an adjunct or alternative for analgesia.
• Topical NSAIDs (diclofenac gel) for localized relief with fewer systemic side effects.
• Systemic corticosteroids are **not recommended** because they increase rupture risk.

Physical therapy & rehabilitation

1. Early gentle range‑of‑motion exercises (within 48–72 h) to prevent stiffness.
2. Eccentric strengthening – proven to improve tendon healing (e.g., heel‑drop for Achilles).
3. Gradual progression – increase load only when pain‑free; typical timeline 6–12 weeks.

Surgical intervention

Reserved for complete ruptures or chronic tendonitis unresponsive to conservative care after 3–6 months. Procedures include tendon repair, grafting, or reconstruction.

Adjunctive therapies

• Platelet‑rich plasma (PRP) – emerging evidence suggests benefit in tendon healing, though data remain limited (Cleveland Clinic, 2020).
• Low‑level laser therapy (LLLT) – may reduce pain; use as part of a multimodal plan.

Living with Quinolone‑Associated Tendonitis

Daily management tips

• Footwear – wear supportive shoes with cushioned heels; consider orthotics for Achilles involvement.
• Activity modification – avoid running, jumping, or heavy lifting until cleared by a therapist.
• Heat & cold – alternate ice (acute phase) and heat (later stages) to improve circulation.
• Hydration & nutrition – adequate protein, vitamin C, and omega‑3 fatty acids support collagen repair.
• Weight management – excess body weight increases tendon load, especially on the knees and ankles.
• Regular follow‑up – schedule appointments with your primary care provider or orthopedic surgeon to monitor healing.

Return‑to‑activity guideline

1. Pain‑free full range of motion.
2. Strength at least 80 % of the uninvolved side (determined by manual muscle testing).
3. Successful completion of functional drills (e.g., single‑leg hop for Achilles) without pain.
4. Physician/therapist clearance before resuming high‑impact sports.

Prevention

• Prescribe fluoroquinolones only when necessary – follow antimicrobial stewardship guidelines.
• Screen for risk factors before starting therapy; choose an alternative (e.g., β‑lactam, macrolide) in high‑risk patients.
• Educate patients to stop the drug and report any tendon pain immediately.
• Avoid concurrent steroids whenever possible.
• Encourage gradual activity – advise patients to limit vigorous exercise during and for at least two weeks after therapy.
• Maintain good hydration and nutrition, especially for older adults.

Complications

If untreated or unrecognized, quinolone‑associated tendonitis can progress to:

• Tendon rupture – Achilles ruptures require surgical repair and entail a prolonged rehabilitation (6–12 months).
• Chronic tendon degeneration (tendinosis) – persistent pain and functional limitation.
• Reduced mobility – especially in the elderly, leading to falls and secondary injuries.
• Compartment syndrome – rare, but can occur after a rupture with swelling.

When to Seek Emergency Care

References

1. U.S. Food & Drug Administration. Fluoroquinolone Antimicrobial Drugs: FDA Drug Safety Communication. 2016. URL
2. Centers for Disease Control and Prevention. Antibiotic Use and Resistance. 2022. URL
3. Mayo Clinic. Fluoroquinolone side effects: tendon and joint pain. 2023. URL
4. NIH National Library of Medicine. Fluoroquinolone‑induced tendinopathy: a review of mechanisms. 2015. PMCID
5. Cleveland Clinic. Platelet‑rich plasma (PRP) for tendon injuries. 2020. URL
6. World Health Organization. WHO Guidelines on Use of Antimicrobials for Common Infections. 2021. URL